Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flibanserin
- Development stage
- Approved
- Lead developer
- Sprout Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Flibanserin is a small molecule drug approved for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It was originally developed as an antidepressant by Boehringer Ingelheim but was repurposed after showing efficacy in increasing sexual desire. Flibanserin acts as a serotonin receptor modulator, functioning as an agonist at serotonin 5-HT1A receptors and antagonist at 5-HT2A receptors, which leads to changes in levels of neurotransmitters such as serotonin, dopamine, and norepinephrine in the brain. This modulation is thought to increase sexual desire and reduce distress related to low libido[1][5][7][10].
- Brand names
- Addyi
- Other names
- flibanserin
02
Targets
DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))
Beyond the preview
Go deeper on flibanserin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flibanserin.